Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells

Cancer Res. 2000 Sep 15;60(18):5310-7.

Abstract

Endothelin (ET)-1 is produced in ovarian carcinoma cells and is known to act through ET(A) receptors as an autocrine growth factor in vitro and in vivo. In OVCA 433 human ovarian carcinoma cells, ET-1 caused phosphorylation of the epidermal growth factor receptor (EGF-R) that was accompanied by phosphorylation of Shc and its recruitment complexed with Grb2. These findings suggested that an EGF-R/ras-dependent pathway may contribute to the activation of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (Erk) 2 and mitogenic signaling induced by ET-1 in these cells. Specific inhibition of EGF-R kinase activity by tyrphostin AG1478 prevented ET-1-induced transactivation of the EGF-R, as well as Shc phosphorylation and recruitment with Grb2. Furthermore, ET-1-induced activation of Erk 2 was partially inhibited by tyrphostin AG1478. In accord with this finding, the mitogenic action of ET-1 in OVCA 433 cells was also significantly reduced by a concentration of tyrphostin AG1478 that abolished the growth response of EGF-stimulated cells. Inhibition of protein kinase C activity, which contributes to the proliferative action of ET-1 in OVCA 433 cells, had no effect on the activation of Erk 2 by ET-1, which suggests that this effect of protein kinase C does not involve ras-independent activation of Erk 2. Inhibition by wortmannin of PI3-kinase activity, which has been implicated in ET-1 and other G protein-coupled receptor (GPCR)-mediated signaling pathways, reduced Erk 2 activation by ET-1 but had no effect on ET-1-induced EGF-R and Shc phosphorylation. These findings indicate that ET-1-induced stimulation of Erk 2 phosphorylation, and mitogenic responses in OVCA 433 ovarian cancer cells are mediated in part by signaling pathways that are initiated by transactivation of the EGF-R.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adaptor Proteins, Signal Transducing*
  • Adaptor Proteins, Vesicular Transport*
  • Cell Division / drug effects
  • Endothelin Receptor Antagonists
  • Endothelin-1 / antagonists & inhibitors
  • Endothelin-1 / pharmacology*
  • Enzyme Activation
  • Enzyme Inhibitors / pharmacology
  • Epidermal Growth Factor / pharmacology
  • ErbB Receptors / genetics
  • ErbB Receptors / metabolism
  • ErbB Receptors / physiology*
  • Female
  • GRB2 Adaptor Protein
  • Humans
  • MAP Kinase Signaling System / drug effects
  • MAP Kinase Signaling System / physiology*
  • Mitogen-Activated Protein Kinase 1 / antagonists & inhibitors
  • Mitogen-Activated Protein Kinase 1 / metabolism
  • Ovarian Neoplasms / enzymology
  • Ovarian Neoplasms / metabolism
  • Ovarian Neoplasms / pathology*
  • Peptides, Cyclic / pharmacology
  • Phosphoinositide-3 Kinase Inhibitors
  • Phosphorylation
  • Protein Kinase C / antagonists & inhibitors
  • Proteins / metabolism
  • Quinazolines
  • Receptor, Endothelin A
  • Shc Signaling Adaptor Proteins
  • Src Homology 2 Domain-Containing, Transforming Protein 1
  • Transcriptional Activation
  • Tumor Cells, Cultured / drug effects
  • Tyrosine / metabolism
  • Tyrphostins / pharmacology

Substances

  • Adaptor Proteins, Signal Transducing
  • Adaptor Proteins, Vesicular Transport
  • Endothelin Receptor Antagonists
  • Endothelin-1
  • Enzyme Inhibitors
  • GRB2 Adaptor Protein
  • GRB2 protein, human
  • Peptides, Cyclic
  • Phosphoinositide-3 Kinase Inhibitors
  • Proteins
  • Quinazolines
  • Receptor, Endothelin A
  • SHC1 protein, human
  • Shc Signaling Adaptor Proteins
  • Src Homology 2 Domain-Containing, Transforming Protein 1
  • Tyrphostins
  • RTKI cpd
  • Tyrosine
  • Epidermal Growth Factor
  • ErbB Receptors
  • Protein Kinase C
  • Mitogen-Activated Protein Kinase 1
  • cyclo(Trp-Asp-Pro-Val-Leu)